▲ +695.45% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Mallinckrodt in the last 3 months. The average price target is $2.63, with a high forecast of $4.00 and a low forecast of $1.50. The average price target represents a 695.45% upside from the last price of $0.33.
The current consensus among 8 investment analysts is to hold stock in Mallinckrodt. This Hold consensus rating has held steady for over two years.
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.